High-risk stocks have soared since the March selloff. As the author of today’s article observes, “In essence, most investors on Wall Street are positioning for a ‘risk-on’ trade, on the idea that today’s risks will blow over and tomorrow’s rewards will be quite huge.” He proceeds to take a deeper look at 10 high-risk stocks that have been charging higher despite their prevailing risks – and whether any might be worth buying on the heels of their surges. For more, CLICK HERE.
“If you are looking to hit a home run in the stock market, the NASDAQ Composite is a good place to start,” advises the author of today’s article, pointing to its thriving technology and biotech stock constituents and strong performance amid the pandemic. When it comes to which specific stocks may be poised to take off, he recommends looking to the analysts for guidance – and highlights three micro-cap stocks with “Strong Buy” consensus ratings from analysts and upside potential over 120%. For more, CLICK HERE.
When it comes to biotech stocks, the author of today’s article advises that “While you can get access to many of these firms via exchange-traded funds…individual equities will typically give you more ‘bang for the buck’ if you’re willing to accept more risk.” He proceeds to highlight five booming individual biotech stocks to buy based on their year-to-date gains of 30% or greater and game-changing technologies that give them plenty of room to run. For more, CLICK HERE.
The two small-cap biotech stocks highlighted in today’s article appear poised to dominate this year and beyond. Why? As the author explains, “Both companies are pioneers in their respective spaces and offer robust pipelines, with lead products nearing the middle of the drug-development process.” For more on these two under-the-radar biotech stocks – and the science and potential related to their products – CLICK HERE.
The stock market could be in for an especially volatile time this week and into July – and while the acceleration in new coronavirus cases would be a major factor driving that volatility, it would not be the only factor. As the author of today’s article explains, “there are a number of factors that also have the potential to exacerbate volatility in financial markets next week and into July” – and he outlines seven of them. For more, CLICK HERE.
“This pandemic-driven frenzy for drugmaker stocks has made it awfully hard for investors who like to focus on the fundamentals,” notes the author of today’s article – and as a result he proceeds to highlight two biotech stocks which have upcoming catalysts that have nothing to do with COVID-19. While one of these stocks may be too risky for most at the moment, the other could be a buy right now. For more, CLICK HERE.
If you’re looking for an options trade with the potential to nearly double your money, today’s article outlines one such trade to consider. Specifically, as the author explains, “It’s a play on the coming boom in housing. While the pandemic put the brakes on it, the housing industry is already starting its unexpected comeback. And why is ‘unexpected’ important? Because a lot of people will be looking elsewhere for opportunities, and that leaves bargains for us.” For more, CLICK HERE.
“Against this backdrop, investors will need to crunch the numbers, to find the stocks that are best positioned for current conditions,” advises the author of today’s article – and based on the aggregation of eight separate factors commonly used to predict results, each of the three stocks highlighted in today’s article is a “Perfect 10”. For these three stocks that appear to be compelling plays in the current environment, CLICK HERE.
Could a COVID-19 vaccine – or vaccines – be approved before the November election? That’s the bold prediction being made by Jefferies – and if the major biotechnology investing research firm is correct, it would be a big deal for investors. The author of today’s article, however, argues that, “Ironically, early vaccine approvals probably won’t mean much for investors who have already enjoyed good runs in vaccine developers” – and points to other parts of the market that could be the real winners. For more, CLICK HERE.
In the cancer treatment space, today’s article highlights two small-cap biotech names to consider this month based on their attractive prices and potential to “take the oncology market by storm.” As the author explains, “Both companies have first-in-class therapies at the cutting edge of science. One company received approval from the Food and Drug Administration (FDA) for its cancer drug and is expanding to other indications. Another offers a promising pipeline with a strong patent portfolio that is in the process of regulatory submission.” For more, CLICK HERE.